AngioDynamics, Inc. (ANGO) AI Stock Analysis

AngioDynamics, Inc. designs, manufactures, and distributes medical, surgical, and diagnostic devices used globally across oncology, vascular access, and peripheral vascular disease. Established in 1988 and based in Latham, New York, the company provides products such as the NanoKnife and Solero microwave tissue ablation systems for cancer treatment and surgical ablation. Its portfolio also features angiographic catheters, guidewires, and drainage systems utilized in thrombus management, atherectomy, and venous insufficiency procedures. AngioDynamics sells directly and through distribution partnerships to interventional radiologists, cardiologists, vascular surgeons, oncologists, urologists, and critical care nurses.

Revenue grew from $316.2M in FY2022 to $338.8M in FY2023, before declining 10.3% to $303.9M in FY2024 and 3.8% to $292.5M in FY2025. In FY2026, revenue rebounded 9.5% to $320.2M, representing a 5-year revenue CAGR of 1.9% from FY2021. Gross margin expanded to 54.6% in FY2026 from 50.9% in FY2024. Operating margin remained negative at -12.5% in FY2026, and net income was -$36.7M, narrowing from -$184.3M in FY2024. For the trailing twelve months ended August 31, 2026, revenue reached $325.4M with quarterly revenue growth of 6.9% year-over-year, while profit margin was -10.1% and EPS was -$0.78.

As of August 31, 2026, AngioDynamics held $34.0M in cash and short-term investments against $10.7M in total debt, leaving net cash of $23.2M. The company reported shareholders' equity of $164.0M, a debt-to-equity ratio of 0.07, and a current ratio of 2.40. In FY2026, operating cash flow reached $3.1M, funding capital expenditures of $2.6M and generating free cash flow of $508,000. Over five years, the company's share count grew by 7.6%.

At $11.24 per share, AngioDynamics carries an enterprise value of $601.3M and an EV-to-EBITDA multiple of 960.6x, compared to 12.0x for the median of its US-listed Healthcare peers. Its forward P/E stands at 96.2x versus the peer median of 17.3x, while its price-to-sales ratio of 1.5x sits below the peer median of 4.1x. Over the past year, ANGO delivered a return of -4.1%, trailing the S&P 500 (SPY) return of 16.8%. Over five years, the stock returned -58.9% compared to 83.0% for the S&P 500.

AngioDynamics holds 4 Strong Buy ratings and no Buy, Hold, Sell, or Strong Sell recommendations. The mean price target of $19.75 implies 75.7% upside versus the last close of $11.24. For the fiscal year ending May 31, 2027, consensus estimates anticipate revenue of $337.7M and an EPS of -$0.28. For the following fiscal year, 3 analysts project revenue of $354.9M and an EPS of -$0.11. The company has beaten EPS expectations in 3 of the last 4 quarters.

This page is an AI-written research summary of AngioDynamics, Inc. (ANGO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ANGO income statement, ANGO balance sheet, ANGO key metrics, ANGO analyst forecast, ANGO chart. See the ANGO stock overview for the latest quote and news.